Management Presentation
Attractive market fundamentals | Leadership and scale | Multiple growth drivers Margin improvement | Attractive financial outlook | Compelling sustainability story
Rigorously focused on improving core EBITDA margin
to ~24-26% by 2028
Operational improvement
C
A
Volume, price
and product mix
Growing share of higher
margin products and
portfolio simplification
B
Network
design
Internal and external
network simplification
Focused
vertical
integration
Establish vertically
integrated Biosimilars
supply
Operational
excellence
Continue to increase
manufacturing
productivity
Procurement
optimization
Focus on long-term
partnerships and scale
Organizational
efficiency
Efficiencies through a
leaner operating model
~200bps
~350bps
Core EBITDA margin expansion from ~18-19% in 2023 to ~24-26% by 2028
Included in business plan
Note: For additional information regarding the core results, which are non-IFRS measures, see "Appendix" starting on slide 31
~150bps
17
Management Presentation
SANDOZView entire presentation